Amicus Therapeutics (NASDAQ: FOLD) CDO reports Form 4 stock disposals

Rhea-AI Filing Summary

Amicus Therapeutics Chief Development Officer Jeff Castelli filed a Form 4 reporting two non-derivative transactions in the company’s common stock. On January 2, 2026, a transaction coded “F” involved the disposition of 6,905 shares at $14.27 per share, leaving 432,413 shares beneficially owned directly.

On January 3, 2026, a second “F” coded transaction reported the disposition of 23,102 shares at $14.27 per share, resulting in 409,311 shares of common stock beneficially owned directly after the transaction.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Castelli Jeff

Role Chief Development Officer

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	23,102	$14.27	$330K
Tax Withholding	Common Stock	6,905	$14.27	$99K

Holdings After Transaction: Common Stock — 409,311 shares (Direct)

Footnotes (1)

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Castelli Jeff

(Last) (First) (Middle)

47 HULFISH STREET

(Street)

PRINCETON NJ 08542

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS, INC. [ FOLD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		F		6,905	D	$14.27	432,413	D
Common Stock	01/03/2026		F		23,102	D	$14.27	409,311	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Christian Formica, Attorney-in-Fact	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the latest Form 4 for FOLD report about insider activity?

The Form 4 reports that Jeff Castelli, Chief Development Officer of Amicus Therapeutics, disposed of common stock in two transactions coded “F” on January 2 and 3, 2026 at $14.27 per share.

Who is the reporting person in the Amicus Therapeutics (FOLD) Form 4?

The reporting person is Jeff Castelli, an officer of Amicus Therapeutics serving as Chief Development Officer.

How many Amicus Therapeutics (FOLD) shares were involved in the reported transactions?

The Form 4 shows dispositions of 6,905 shares of common stock on January 2, 2026 and 23,102 shares on January 3, 2026, both at $14.27 per share.

How many Amicus Therapeutics (FOLD) shares did Jeff Castelli own after the Form 4 transactions?

After the January 2, 2026 transaction, Jeff Castelli beneficially owned 432,413 shares of common stock directly, and after the January 3, 2026 transaction he beneficially owned 409,311 shares directly.

Were the reported Amicus Therapeutics (FOLD) transactions direct or indirect holdings?

The Form 4 indicates that the transactions and resulting holdings are direct, as shown by the ownership form “D” in the filing.

What transaction code is used in the FOLD Form 4 and what does it signify?

Both entries use transaction code “F”, indicating a disposition of common stock under the Form 4 instructions, with 6,905 and 23,102 shares respectively at $14.27 per share.